FDA Approves Second CAR T-cell Therapy

This is the authors' abstract. We don't add key points for this paper.

The FDA approved the chimeric antigen receptor T-cell therapy axicabtagene ciloleucel, making it the second such treatment for blood cancers in the United States. The therapy is indicated for adults with certain non-Hodgkin lymphomas who have tried at least two other treatments.